The majority of approvals were in metastatic disease (76%); in this setting, more than 60% were issued in hormone receptor-positive/HER2-negative patients and of them, 80% concerned a CDK4/6 inhibitor. The gene discussed is ERBB2; the disease is metastatic neoplasm.